Multiple sclerosis
A six-month programme designed to help participants change their eating and lifestyle habits led to significant weight loss in people living with multiple sclerosis (MS) and obesity, new research revealed.
People who develop Multiple Sclerosis (MS) are more likely to have a number of underlying conditions years before their diagnosis, a new study reveals.
The injection of a type of stem cell into the brains of patients living with progressive multiple sclerosis (MS) has a long-lasting effect that appears to protect the brain from further damage, new research has found.
Multiple sclerosis (MS) patients with elevated levels of nerve biomarker NfL in their blood are at an increased risk of worsening disability within two years, new research led by UC San Francisco suggests.
NR Times reports on seven innovative projects changing the outlook for multiple sclerosis.
MS is a complex and unpredictable autoimmune disease of the central nervous system, affecting millions of people worldwide. The condition was previously deemed untreatable but over the last 20 years huge strides have been made in understanding MS, its causes and potential treatments. In recent months, ongoing efforts continue to deepen our comprehension of the condition, from EBV vaccine breakthroughs to the discovery of genetic variants responsible for speeding up MS progression.By Norman Putzki (MD PhD), global head development neuroscience and gene therapy at Novartis.
Over the last 30 years, remarkable progress has been made in the advancement of treating multiple sclerosis (MS), a potentially disabling disease that is most likely a consequence of complex autoimmune dysfunctions in the periphery ultimately leading to demyelination in the central nervous system (CNS).
Since 1993, a series of insights has led to greater understanding of the biological mechanisms and triggers driving the inflammatory attacks on the CNS.
These translational insights have also driven the development of newer and more effective treatments in MS.
Depression is unlikely to play a role in making disability progression worse in people with multiple sclerosis (MS), a new study published in Scientific Reports has found.
Researchers from Swansea University, University of Cambridge and Queen Mary University of London conducted the UK-wide study to find out if depression and/or anxiety put people with MS at greater risk of disability progression.
Body's fight against Epstein-Barr virus could cause or worsen Multiple Sclerosis, research reveals
A first-of-its-kind technology is boosting the benefit of physical therapy for MS patients through electrical pulses that aim to ‘rewire’ the brain and activate neural pathways. Physical therapy is an essential aspect of treating MS, but it has its limitations. In most cases, MS affects the cerebellum, also known as the brain stem. Physical therapy [...]
As medical director of Holy Name’s renowned MS Center in New Jersey, Dr Mary Ann Picone is a hugely influential figure in the movement to advance MS treatments. NR Times speaks to her about challenges, opportunities and new developments in the MS field. Not so long ago, being diagnosed with MS meant an end to life as you knew it. So bleak was the outlook, recalls Dr Mary Ann Picone, that America’s MS community came up with a phrase soaked in gallows humour – “diagnose and adios”. Although as recently as the 1980s there were virtually no treatment options for clinicians to turn to, however, there are now numerous; and Dr Picone, who has been on the frontline of MS drug development in the decades since, has played an important role in helping to drive this. Read on to find out about the emerging therapies that will shape MS treatment in the coming years and Dr Picone's views on the road ahead in MS research.
